Obinutuzumab

Cat#:	THA-0054
Product Name:	Obinutuzumab
Description:	Obinutuzumab is an antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.
Sequences:	Not Available
Molecular Weight:	146100.0 Da
Introduction:	Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
Purity:	>99% by SDS-Page and HPLC analysis
Formula:	C6512H10060N1712O2020S44
Appearance:	Liquid
Endotoxin Level:	< 0.001 EU/μg of the protein by the LAL method

Pharmacodynamics:	Obinutuzumab is more potent than rituximab in depleting B-cells, antitumor activity, and tumor regression.
Targets:	B-lymphocyte antigen CD20

Catalog#	Product Name	Inquiry
THA-0155	Tisotumab vedotin	Inquiry
THA-0154	Amivantamab	Inquiry
THA-0150	Cilgavimab	Inquiry
THA-0151	Tixagevimab	Inquiry
THA-0152	Regdanvimab	Inquiry
THA-0153	Donanemab	Inquiry
THA-0145	Nirsevimab	Inquiry
THA-0148	Ansuvimab	Inquiry
THA-0149	Axatilimab	Inquiry
THA-0146	Sotrovimab	Inquiry

Specification